Healthcare / BiotechnologyNasdaqCM
$0.83
-0.01 (-1.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-51.8M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$123M
P/E
N/A
•EV/EBITDA
N/A
•ROE
193.9%
↑Gross Margin
4.0%
↓Debt/Equity
-0.94
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
-12.2%
FCF CAGR
—
FCF margin
-3666.7%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.4M · net income $-62.4M · FCF $-51.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $1.4M | $1.4M | — | — | — | — | — | $8.1M | $3.1M | $3.8M | $3.0M | $5.2M |
| Net Income | $-62.4M | $-62.4M | $-75.4M | $-59.0M | $-66.1M | $-53.2M | $-35.2M | $-34.5M | $-30.1M | $-38.8M | $-53.3M | $-47.4M |
| EBITDA | $-63.6M | $-63.6M | $-72.1M | $-56.4M | $-64.4M | $-51.5M | $-36.6M | $-32.9M | $-26.6M | $-33.2M | $-49.0M | $-44.7M |
| EPS | -1.79 | -1.79 | -4.06 | -4.80 | -6.20 | -7.00 | -13.40 | — | -195.20 | -288.00 | -587.20 | — |
| Gross Margin | 4.0% | 4.0% | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -4744.3% | -4744.3% | — | — | — | — | — | -445.6% | -960.1% | -941.4% | -1723.3% | -892.1% |
| Net Margin | -4416.2% | -4416.2% | — | — | — | — | — | -423.8% | -974.6% | -1019.3% | -1788.9% | -908.1% |
| Balance Sheet | ||||||||||||
| Debt/Equity | -0.94 | -0.94 | -0.41 | -2.46 | 1.25 | — | — | -0.00 | -0.00 | -0.00 | -0.43 | -0.05 |
| Current Ratio | 0.54 | 0.54 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-51.8M | $-51.8M | $-68.8M | $-43.0M | $-56.7M | — | — | $-32.7M | $-35.8M | $-15.8M | — | — |
| Returns | ||||||||||||
| ROE | 193.9% | 193.9% | 103.1% | 408.5% | -756.0% | -1153.9% | -1246.8% | 214.0% | 117.8% | 115.4% | 1030.4% | 87.4% |
| Valuation | ||||||||||||
| P/B | — | — | — | — | 30.59 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | 163.8% | -19.0% | 27.9% | -42.9% | — |
| EPS Growth | 55.9% | 55.9% | 15.4% | 22.6% | — | 47.8% | — | — | 32.2% | 51.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.06 → -1.79
Residual
-53.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.